⌕
Janux Therapeutics · JANX · Nasdaq
Tenet 74 · Solid
Compare
$11.37−1.09%At closeTenet 74 · Solid
$11.37−0.13 (−1.09%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Janux Therapeutics (JANX) Stock

Janux Therapeutics (JANX) closed at $11.37 on Nov 13, 2026; its Tenet Score is 74 of 100 against 407 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

25 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$11.37
Nov 13, 2026
Market cap
$695.7M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
11.15 – 35.34
low → high
Tenet Score
74/100
Solid · 407 Healthcare peers

Industry: Drugs · see every company filed here →

Janux Therapeutics Inc scores 74/100. Solid. Strongest on value and financial health, quality is the soft spot versus 407 Healthcare peers. Insufficient inputs: Tenet 74 is built from 3 of 4 pillars, from 40% of its inputs. Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=407
74/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
95
Quality
34
Health
92
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueAQualityDHealthAGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
loss
P/B
0.8×
price to book value
P/S
29.9×
price to fiscal 2025 sales
ROE
−11%
return on equity
Operating margin
−1576.7%
fiscal 2025, before interest and tax
Net margin
−428.7%
of revenue kept
Current ratio
17.69
current assets to liabilities
Net debt / EBITDA
—
no_ebitda
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Janux Therapeutics Inc

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in p…

Composite computed Nov 15, 2026 · peer basis: Healthcare (n=407) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 62 US ETFs · top wrappers by weightSee all ETFs holding JANX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Janux Therapeutics in?

Janux Therapeutics is in the Healthcare sector and the Drugs industry.

What is Janux Therapeutics' Tenet Score?

Janux Therapeutics' Tenet Score is 74 out of 100, ranked against 407 Healthcare peers as of Nov 15, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.